Cardiff Oncology Announces First Patient Dosed in a Phase 2 Trial of Onvansertib in Combination …,

(Nasdaq: CRDF), a clinical-stage biotechnology company developing onvansertib to treat cancers with the greatest medical needs for new treatment …, (Nasdaq: CRDF), a clinical-stage biotechnology company developing onvansertib to treat cancers with the greatest medical needs for new treatment …, Read More

Scroll to Top